Dacomitinib-an irreversible pan-ErbB tyrosine kinase inhibitor (TKI)-causes diarrhoea in 75% of patients. Dacomitinibinduced diarrhoea has not previously been investigated and the mechanisms remain poorly understood. The present study aimed to develop an in-vitro and in-vivo model of dacomitinib-induced diarrhoea to investigate underlying mechanisms. T84 cells were treated with 1-4 lM dacomitinib and resistance and viability were measured using transepithelial electrical resistance (TEER) and XTT assays. Rats were treated with 7.5 mg/kg dacomitinib daily via oral gavage for 7 or 21 days (n 5 6/group). Weights, and diarrhoea incidence were recorded daily. Rats were administered FITC-dextran 2 hr before cull, and serum levels of FITC-dextran were measured and serum biochemistry analysis was conducted. Detailed histopathological analysis was conducted throughout the gastrointestinal tract. Gastrointestinal expression of ErbB1, ErbB2 and ErbB4 was analysed using RT-PCR. The ileum and the colon were analysed using multiplex for expression of various cytokines. T84 cells treated with dacomitinib showed no alteration in TEER or cell viability. Rats treated with dacomitinib developed severe diarrhoea, and had significantly lower weight gain. Further, dacomitinib treatment led to severe histopathological injury localised to the ileum. This damage coincided with increased levels of MCP1 in the ileum, and preferential expression of ErbB1 in this region compared to all other regions. This study showed dacomitinib induces severe ileal damage accompanied by increased MCP1 expression, and gastrointestinal permeability in rats. The histological changes were most pronounced in the ileum, which was also the region with the highest relative expression of ErbB1.
Dacomitinib (PF-00299804) is an orally administered, highly selective irreversible small-molecule pan-ErbB receptor tyrosine kinase inhibitor (TKI) under development for treatment of recurrent or metastatic non-small cell lung cancer (NSCLC). 1 It acts by covalently binding to the intracellular adenosine triphosphate domain of each of the three kinaseactive members of the ErbB family (ErbB1, ErbB2 and ErbB4). This effectively inhibits phosphorylation of the receptors and therefore downstream signaling. 2 In addition to being expressed on cancer cells, the ErbB family are also abundantly expressed on the basolateral membrane of healthy gastrointestinal epithelial cells, and are crucial for essential functions including maintenance of mucosal integrity via induction of mucus and prostaglandin synthesis, promotion of enterocyte migration, prevention of intestinal epithelial cell apoptosis, decreasing bacterial translocation and preservation of gut barrier function after injury. [3] [4] [5] Dacomitinib is currently in Phase III clinical trials for NSCLC and has shown significant therapeutic effects, specifically to tumours which have not previously responded to conventional single receptor inhibitors. 6 Furthermore, dacomitinib has shown to be effective against tumours with mutations developed for acquired resistance of targeted therapies. 7 However a commonly reported adverse event among all trials has been diarrhoea, with up to 78% of patients developing some degree of diarrhoea. 8 Severe diarrhoea commonly results in dose reductions and patient withdrawal from clinical trials. 8 Of particular clinical importance is dacomitinib is delivered in a continuous manner over many months; therefore, to optimise dacomitinib therapy, adequate management or prevention of chronic diarrhoea is essential to minimise the impact on the patient's quality of life, increase safety and the ability to complete the course of therapy. Currently management for dacomitinib-induced diarrhoea follows that used in conventional chemotherapy (daily loperamide), however the mechanisms underlying this diarrhoea are likely different. 9 Recent Phase II research has investigated both antibiotic and probiotic prophylactic treatment for dacomitinib-induced diarrhoea, with no change in diarrhoea reported. 10 It is hypothesised that the development of dacomitinib-induced diarrhoea differs from conventional chemotherapy-induced diarrhoea and does not result due to direct cytotoxicity but rather occurs through alternative mechanisms. 9, 11 As such, traditional diarrhoea management may be not targeting the underlying changes for optimal management. Therefore, this study assessed direct cytotoxicity in an in vitro model, and then aimed to develop an in vivo rat model of dacomitinibinduced diarrhoea, characterising the changes that dacomitinib causes through the gastrointestinal tract.
Material and Methods

Chemicals
Dacomitinib (PF-00299804) was kindly provided by Pfizer Pharmaceuticals. For all in vivo experiments dacomitinib was suspended in 0.5% (w/w) hydroxypropyl-methylcellulose to a final concentration of 2 mg/ml. For all in vitro experiments dacomitinib was suspended in DMSO. SN38 and TX100 were used as positive controls in vitro, both suspended in DMSO. Exposure of DMSO to cells did not exceed 0.01%.
In vitro model
The model utilised T84 cells (passage 5-15) derived from a human colorectal carcinoma (Culture Collections, Porton Down, UK). Cells were authenticated by Culture Collections by DNA profiling and were used within 6 months of receipt. Cells were maintained at 378C in 5% CO 2 /95% air in Dulbecco's Modified Eagle Medium (DMEM)/Ham's F-12 Nutrient Mixture containing 15 mM HEPES, L-glutamine and 10% foetal bovine serum (FBS) and were routinely screened for mycoplasma infection. Cells were seeded at a density of 100,000 cells/cm 2 on 1.12 cm 2 , 0.4 lm pore polyester transwell inserts (Corning Life Sciences, MA) or at 10,000 cells in 96 well microtiter flat-bottom plates (Becton Dickinson) for transepithelial electrical resistance (TEER) measurements and cell proliferation (XTT) assays (Roche, Australia) respectively. Dacomitinib was diluted to a series of concentrations (1-4 lM) and exposed to cells via the apical side for 24-48 hr. An equivalent dilution of DMSO was used as vehicle control treatment. SN-38 (5 lM), an inhibitor of topoisomerase 1, was used as the positive control as it is recognised for its cytotoxicity.
12 Triton X-100 was used as the positive control for TEER measurements as it is known to permeabilise T84 cells. 13 All experiments were performed in triplicate and repeated twice. Polyester transwell inserts support a polarised T84 phenotype with functional tight junctions; TEER is a measure to assess the integrity of this monolayer. 13 Once cells had reached 1,000 X/cm 2 , indicating monolayer formation, cells were exposed to varying doses of dacomitinib for 24 or 48 hr. Transepithelial electrical resistance (TEER) was measured using an EVOM2 epithelial volt-ohm-meter with chopstick electrodes, STX2 (World Precision Instruments, Sarasota, FL) and area adjusted for analysis using the following formula; XTT assays were conducted on cells exposed to 1-4 lM dacomitinib in total media for 24 hr. Following 24 hr exposure, media and dacomitinib were removed and replaced with 100 ll fresh media and 50 ll of XTT solution; composed of 5 ml XTT labelling reagent and 100 ll of electron coupling reagent (Roche cell proliferation kit, Germany). The microtitre plate was incubated again for 6 hr at 378C in 5% CO 2 /95% air. Absorbance was read at 490 nm using Bio Tek Synergy TM Mx Microplate Reader (Bio Tek, Vermont) and Gen5 version 2.00.18 software to assess the cleavage of tetrazolium salt XTT in the presence of an electron-coupling reagent, producing a soluble formazan salt, only occurring in viable cells.
In vivo model and ethics
The study was approved by the Animal Ethics Committee of The University of Adelaide, and complied with the National Health and Medical Research Council (Australia) Code of Practice for Animal Care in Research and Training (2014). Rats were group housed in ventilated cages with three to six animals per cage and were on a 12 hr light/dark cycle. Food and water were provided ad libitum.
Experimental design
All experiments were conducted on male Albino Wistar rats (initial age 6 weeks) obtained from The University of What's new? Dacomitinib can hunt down and kill tumor cells that resist other chemotherapy drugs. But the same receptor family that dacomitinib seizes in tumor cells-the ErbB family-also adorn healthy gastrointestinal epithelial cells, causing most patients to suffer from dacomitinib-induced diarrhea. These authors sought to understand the mechanism behind this, in hopes of managing it. In rats, they observed that dacomitinib caused severe injury to the ileum, which is the region with the highest ErbB1 expression, and gastrointestinal permeability. Inflammation by monocyte infiltration also seems likely to contribute to the damage, since they observed increased MCP-1 in the ileum.
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Adelaide Laboratory Animal Service (SA, Australia). Rats were treated with dacomitinib at a dose of 7.5 mg/kg administered daily for 7 or 21 days, via oral gavage using a soft plastic feeding tube. This treatment schedule mimics the clinical oral administration over many weeks and allows assessment of acute damage (7 days) and prolonged damage (21 days). Control animals received daily gavage with dacomitinib vehicle (0.5% [w/w] hydroxypropyl-methylcellulose). Rats were randomly assigned to treatment groups and culled at 7 and 21 days (n 5 6/group). Rats were anaesthetised using isoflurane inhalation, and were culled via cardiac exsanguination and cervical dislocation.
Clinical assessment of gastrointestinal toxicity
All rats were monitored two times daily for the presence of diarrhoea. Two independent assessors quantified diarrhoea using a validated grading system where 0 5 no diarrhoea, 1 5 mild diarrhoea with soft stools and perianal staining, 2 5 moderate diarrhoea with loose stools and perianal staining of fur, 3 5 severe diarrhoea with watery stools 6 mucous and fur staining incorporating hind legs. 14 Rats were weighed daily to track weight loss/gain. Rats were culled if they displayed > 15% weight loss or significant distress and deterioration, in compliance with animal ethical requirements. One animal was removed from the study due to > 15% weight loss from the dacomitinib group. This animal was not included in any further analysis.
Tissue preparation
At necropsy, the entire gastrointestinal tract from pyloric sphincter to rectum was dissected and flushed with saline to remove intestinal contents. Samples of jejunum, ileum and colon were collected and either (i) fixed in 10% formalin for embedding in paraffin, (ii) had the mucosal surface scraped and stored in RNA-later at 2208C for molecular analyses, or (iii) had the mucosal surface scraped and snap frozen in liquid nitrogen and stored in 2808C for immunological analysis. Other organs were collected as routine and fixed in formalin and embed in paraffin. All histopathological analysis was conducted on 5 lm sections tissue cut on a rotary microtome and mounted onto glass SuperfrostV R microscope slides (Menzel-Gl€ aser, Braunschweig, Germany). Slides were scanned using a NanoZoomer TM (Hamamatsu Photonics, Japan) and assessed with NanoZoomer Digital Pathology software view.2 (Histalim, Montpellier, France).
Blood biochemistry
Blood samples were collected by cardiac puncture. Serum was separated by centrifugation at 3,000g for 5 min before being analysed by the Department of Clinical Pathology, SA Pathology, Adelaide, South Australia. A multiple blood analysis (MBA-20) was conducted.
Gastrointestinal histopathological analysis
Haematoxylin and eosin (H&E) staining was performed and a well described total tissue injury score was generated based on the occurrences of eight histological criteria in the jejunum and ileum, and six criteria in the colon. 15, 16 These criteria were villous fusion and villous atrophy (jejunum and ileum only), disruption of brush border and surface enterocytes, crypt loss/architectural disruption, disruption of crypts cells, infiltration of polymorphonuclear cells and lymphocytes, dilation of lymphatic's and capillaries and oedema. Each parameter was scored as present 5 1, or absent 5 0, in a blinded fashion.
Goblet cell analysis
Alcian Blue (1% Alcian Blue 8GX (CI 74240) in 3% glacial acetic/Periodic acid Schiff staining was performed on jejunum, ileum and colon. Sections were oxidised in 1% periodic acid before washing then treated in Schiff's reagent. Goblet cells and cavitated cells in crypts and villi that were deemed to be >80% complete were counted, and a total of at least 15 villi/crypts per section analysed. Data presented as average per crypt or villous. All analysis was done in a blinded fashion.
Immunohistochemistry
Immunohistochemical analysis was performed for apoptosis (caspase 3; Abcam, Vic, Australia; #ab4051), and proliferation (Ki67; Abcam, Vic, Australia #ab16667). Changes in these parameters are validated markers for altered tissue kinetics in previous models of cancer therapy induced-gastrointestinal toxicities. [17] [18] [19] [20] Immunohistochemical analysis was performed using Dako reagents on an automated machine (AutostainerPlus TM , Dako, Denmark) following standard protocols supplied by the manufacturer. Briefly, sections were deparaffinised in histolene and rehydrated through graded ethanol before undergoing heat mediated antigen retrieval using an EDTA/Tris buffer (0.37 g/L EDTA, 1.21 g/L Tris; pH 9.0). Retrieval buffer was preheated to 658C using the Dako PT LINK (pre-treatment module). Slides were immersed in the buffer and the temperature raised to 978C for 20 min. After returning to 658C, slides were removed and placed in the Dako AutostainerPlus and stained following manufactures guidelines. Negative controls had the primary antibody omitted. Caspase 3 and Ki67 were quantified by counting the number of positively stained cells for 15 crypts. Data presented as average positively stained cells per crypt. All analysis was done in a blinded fashion.
Real time PCR
To asses the expression of ErbB1, ErbB2 and ErbB4 receptors along the gastrointestinal tract, total RNA was isolated from duodenal, jejunal, ileal and colonic mucosal scrapings. Purification of mRNA was done using the Nucleospin mRNA purification RNA II kit (Macherey-Nagel) following the manufacturer's protocol. RNA (1 lg) was reverse transcribed using iScriptTM cDNA synthesis kit (Bio-Rad) according to the manufacturer's protocol. cDNA was quantified and diluted to a working concentration of 100 ng/ll. Primers for genes of interest were either designed using web-based primer design program Primer 3, version 4 (http://bioinfo.ut.ee/ primer3-0.4.0/), or in the case of ErbB4 purchased from BioRad (Gladesville, Australia). Genes of interest were ErbB1 (Forward: 5'-CCCACAGCAAGCCTTCTTCA; Reverse: R: 5'-CACGGCAGCTCCCATTTCTA), ErbB2 (Forward: 5'-GCTCCTCCTTGAGTTGAGTGT; Reverse: 5'-TAGCCTTG-GAATGAGTGCGT) and ErbB4 (PrimePCR TM SYBRV R Green Assay: ErbB4, rat). ErbB1 and ErbB2 were denatured at 958C for 10 sec, annealed at 528C for 15 sec, and extended at 728C for 20 sec (40-45 cycles). ErbB4 was following manufactures instructions. Amplified transcripts were detected by SYBR Green (Quantitect, Qiagen) in a Rotor-Gene Q (Qiagen). All reactions were completed in triplicate, with two housekeeping normaliser primers, UBC (Forward: 5'-TCGTACCTTTCTCA CCACAGTATCTAG; Reverse: 5'-GAAAACTAAGACACCT CCCCATCA) and B2M (Forward: 5'-TGACCGTGATCTTT CTGGTG; Reverse: 5'-ATCTGAGGTGGGTGGAACTG). Amplification was followed by a melt curve analysis to confirm product specificity. Relative gene expression was determined by delta Ct method. 21 
Tissue cytokine quantification
Proinflammatory cytokine expression was assessed using 30 mg of ileal and colonic mucosal scraping samples. Mucosa samples were homogenised at room temperature using the QIAGEN TissueLyser LT (Qiagen) for 5 min at 50 Hz in 500 lL of the Radioimmunoprecipitation Assay (RIPA) buffer (150 mmol/L NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS and 50 mmol/L Tris, pH 8.0; Sigma Aldrich; #04693116001). Homogenates were centrifuged at 11,000g for 15 min at 48C and the supernatant isolated, aliquoted, and stored at 2808C. Total protein concentration was quantified using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific; #23225). A working concentration of 1 mg/ml was used for cytokine analysis. Levels of 7 different cytokines, including interleukin-1b (IL-1b), interleukin-6 (IL-6), interleukin-17 (IL-17), tumour necrosis factor alpha (TNFa), monocyte chemoattractant protein-1 (MCP-1), interleukin-4 (IL-4) and interleukin-10 (IL-10), were measured in individual ileal and colonic homogenates using Luminex xMAP technology (Milliplex Rat Cytokine Kit, Merck Millipore; #RECYTMAG-65 K) as per the manufacturer's instructions. Each 96 well plate included a 6-point standard curve and two quality controls provided by Merck Millipore.
FITC-dextran assay
Two hours prior to culling, rats received a 600 mg/kg dose (120 mg/ml) of 4 kDa fluorescein isothiocyanate (FITC)-dextran (Sigma-Aldrich, NSW, Australia, Cat# FD4) via oral gavage. Blood was collected via cardiac puncture at necropsy into serum-gel clotting activator tubes and protected from light. Samples were centrifuged at 3,000g for 5 min and serum isolated. Serum samples were diluted 1:3 with 1 X PBS and quantified using the Bio Tek Synergy TM Mx Microplate Reader (Bio Tek, Vermont) and Gen5 version 2.00.18 software relative to a standard curve (range 0.0001-10 lg/ml).
Statistical analysis
Data were compared using Prism version 7.0 (GraphPadV R
Results
Dacomitinib does not cause direct cytotoxicity to T84 epithelial cells T84 monolayers exhibited comparable TEER between controls and monolayers treated with dacomitinib (1-4 lM), with no significant differences detected (p > 0.05). TEER readings for cells treated with all doses of dacomitinib were significantly higher than SN38, the positive control (p < 0.05; Fig. 1a ). Cells treated with varying doses of dacomitinib (1-4 lM) had no alterations in cell viability, as measured by XTT absorbance, with no significant differences seen between controls (Fig. 1b) . Compared to the positive control (SN38), cells treated with dacomitinib had significantly increased viability (p < 0.05; Fig. 1b) . Combined, these results demonstrate that dacomitinib does not cause direct cytotoxicity to T84 cells.
Dacomitinib causes reproducible, severe diarrhoea
Rats treated with vehicle control did not develop diarrhoea at any time point (data not shown). Dacomitinib treatment induced diarrhoea in 100% of rats (Fig. 2a) , comparable to the incidence seen in clinical trials. 8 Mild diarrhoea developed in a small number of animals from as early as Day 2 of treatment, with severe diarrhoea manifesting as early as Day 3. Diarrhoea incidence peaked from Day 7 onward. The average number of days with diarrhoea was 14 days. Rats treated with dacomitinib had significantly worse diarrhoea than control rats (p < 0.0001).
Growth rates of dacomitinib treated rats were significantly lower than control rats from Day 10 (p < 0.0001; Fig. 2b) . At Day 21, the control group had gained 46.38 6 2.459% body weight compared to Day 1, and the dacomitinib group had gained 18.99 6 5.602% body weight compared to Day 1.
Dacomitinib alters biochemistry and histology
In rats treated with dacomitinib, serum biochemistry revealed mildly elevated alanine aminotransferase (ALT) which, in the
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absence of histological changes in the liver, suggested increased permeability of hepatocyte cell membranes with leakage of this cytosolic enzyme into the blood (Supporting Information Table 1 ). There was also a modest increase in blood urea nitrogen (BUN) and creatinine, particularly at 21 days, indicating mild renal dysfunction (Supporting Information Table 1 ). A mild hypoalbuminaemia was probably attributable to a combination of malabsorption due to villous atrophy, protein-losing enteropathy associated with severe diarrhoea, and renal proteinuria. All other MBA-20 analytes were within the normal range (Supporting Information Table  1 ). Kidneys of all rats, except one, treated with dacomitinib for 21 days showed acute papillary necrosis with severe coagulation necrosis of medullary tubules and collecting duct epithelium, either complete or with intraluminal, desquamated, necrotic epithelial cells and few, usually degenerating, lining epithelial cells with marked interstitial congestion. One rat treated with dacomitinib for 21 days showed mild hydronephrosis, with dilation of renal pelvis and patchy distension of tubules and collecting ducts. Rats treated with dacomitinib for 7 days exhibited mild glomerulopathy with thickening of the glomerular basement membranes.
Dacomitinib causes significant ileal damage
Rats treated with dacomitinib had significant ileal injury compared to controls at both time points (p < 0.0001). This was predominantly characterised by severe villus atrophy with stunting and fusion of villi, which was also attended by enterocyte metaplasia to a low columnar or cuboidal phenotype and mild compensatory expansion of the basal proliferative compartment of crypts. In the congested lamina propria, there was an increased inflammatory infiltrate comprised of lymphocytes, macrophages, plasma cells and neutrophils and dilation of lacteals (villous lymphatics) (Fig. 3 ). There were no significant differences in tissue injury at any time point in the jejunum and colon (data not shown). Across both treatment groups no significant differences for both total number of goblet cells or percentage cavitated goblet cells in the jejunum, ileum or colon as assessed via AB-PAS staining were seen (data not shown).
Dacomitinib did not alter gastrointestinal apoptosis or proliferation
To assess gastrointestinal epithelial apoptosis, the number of caspase-3 positively stained crypt cells were counted and 
ERBb1 receptor is highly expressed in the ileum
The mRNA expression of ErbB1 was significantly higher in the ileum compared to the other regions of the gastrointestinal tract in untreated control rats (p 5 0.0336; Fig. 4 ). The expression of ErbB2 and ErbB4 was unchanged throughout the gastrointestinal tract (p > 0.05). Treatment with dacomitinib did not change the expression of the ErbB receptors (p > 0.05) (data not shown).
Dacomitinib treatment increases levels of monocyte chemoattractant protein-1 (MCP-1) in the ileum
There were significant increases in the expression of MCP-1 in the ileum of rats treated with dacomitinib compared to controls (p 5 0.001). No changes were seen in the colon. Rats treated with dacomitinib showed no statistically significant change in IL-1b, IL-6, IL-17, TNFa, IL-4 and IL-10 expression in the ileum or colon when compared to vehicle controls (Fig. 5) .
Dacomitinib caused increased gastrointestinal permeability
Serum FITC-dextran levels were elevated in rats treated with dacomitinib compared to vehicle controls, (p 5 0.0018; Fig. 6 ).
Discussion
Dacomitinib is an emerging small molecule TKI for the treatment of NSCLC, with clinical trials showing diarrhoea as an adverse event in over 78% of patients. 8 The mechanisms of ErbB TKI-induced diarrhoea are unclear with conflicting hypotheses presented in the literature. 9 The present study found dacomitinib does not cause direct cytotoxicity to T84 epithelial cells, supporting the study hypothesis, and previous literature suggesting that ErbB TKI induced-diarrhoea is not due to direct cell death. 22, 23 However, this may be explained because of the colorectal origin of T84 cells, as in rats dacomitinib causes diarrhoea that appears associated with histopathological alterations in the ileum and intestinal barrier disruption. This is the first time gastrointestinal morphometry and function have been characterised following dacomitinib, demonstrating dacomitinib causes histopathological damage confined to the ileum in rats. In murine models of ErbB TKI-induced gastrointestinal side effects, there has previously been evidence of histological changes characterised by villous atrophy. 11, [24] [25] [26] [27] TKI's have previously been associated with diarrhoea, and this has been largely hypothesised to be of a secretory phenotype. 9, 11 In a previous rat model of lapatinib-induced diarhroea, blood biochemistry showed a significant decrease in serum chloride. This decrease coincided with diarrhoea in rats treated with high-dose lapatinib, suggesting a possible secretory diarrhoea phenotype. 20 However, in the current study we saw no changes in serum chloride suggesting negligible secretory processes. Although not the primary focus of the study, the findings from blood biochemistry indicate rats treated with dacomitinib had significant changes in renal biochemistry, with supplementary histological investigation supporting this. These findings are despite renal clearance of dacomitinib being only minimal. 28 As such, the renal pathology seen in this model is likely to be a species-specific response to high dose dacomitinib. The increased level of liver enzymes seen in the present study is consistent with elevations noted clinically, 28 and are unsurprising given that dacomitinib is largely metabolised by the liver through oxidative and conjugative metabolism. 28 Traditional chemotherapeutic agents are known to cause severe gastrointestinal cytotoxicity, resulting in histological damage manifesting as anatomic derangement diarrhoea. 16, 17 However, throughout the literature there are conflicting findings regarding the histopathological changes in the gastrointestinal tract associated with ErbB TKI-induced diarrhoea. 9 For example, a recent study by Bowen et al. (2012) showed lapatinib-induced diarrhoea was not associated with gastrointestinal histopathological changes, typically associated with anatomic derangement diarrhoea. 14 Hare et al. (2007) showed treatment with gefitninib in a murine model was associated with villous atrophy, confined to the duodenum only. 3 However, Rasmussen et al. (2010) suggested that inhibition of the ErbB receptors with erlotinib causes direct mucosal atrophy and damage, which, similar to this study, was most pronounced in the ileum of mice. 24 This study showed largely negative results, with marginal changes noted in the jejunum or colon. However, significant histopathological changes were noted in the ileum, characterised by significant villus atrophy. Unlike traditional chemotherapy-induced diarrhoea, villus shortening and blunting was localised to the ileum, with terminally differentiated enterocytes being the most affected. There were only mild compensatory changes in the deep crypt progenitor compartment and no associated goblet cell hyperplasia or apoptosis. This supports the hypothesis suggesting an alternative mechanism may be responsible for the changes seen following dacomitinib treatment.
While small intestinal damage has previously been attributed to greater exposure of the unabsorbed drug to the mucosal surface compared to the colon, 29 this is not a plausible explanation in the current study, as the jejunum showed minimal histopathological damage. The differential expression or ErbB receptors through regions of the gastrointestinal tract has not been previously characterised. Data from the present study indicates ErbB1 is preferentially expressed in the ileum compared to other regions of the gastrointestinal tract. It is therefore possible that the high degree of histopathology observed in the ileum may be linked to the high expression of ErbB1. Unlike first generation ErbB TKIs that are susceptible to mutations that affect binding affinity, second generation ErbB TKIs (such as dacomitinib) are irreversible and resistant to mutations, they have therefore demonstrated a higher binding affinity. 30 This may account for the more severe ileal damage seen in our model, and the associated diarrhoea.
Elevated MCP-1 was evident in the ileum, suggesting an inflammatory response characterised, in part, by monocyte infiltration, which may contribute to the ileal tissue injury. This is of particular significance as inflammation has been associated with the induction of a 'leaky' gut. 31, 32 Mucosal enterocyte barrier disruption has been associated with a number of gastrointestinal pathologies characterised by diarrhoea. 33 It has been suggested that altered intestinal permeability worsens clinical outcomes, as it allows for translocation of endotoxin and bacteria. 32 Additionally, it has been proposed that breakdown of the intestinal mucosal barrier contributes to diarrhoea through leak-flux mechanisms allowing passive movement of water into the lumen. 34 Our findings partially support this with increased serum FITCdextran seen following dacomitinib treatment. The increased gastrointestinal permeability noted in this study is most likely indicative of tight junction disruption, the main regulators of paracellular permeability. Tight junctions join the apical margins of adjacent enterocytes and, while permeable to small molecules and water, form a barrier to transepithelial macromolecular movement; the basolateral aspect of enterocytes is Figure 6 . Serum FITC-dextran levels were significantly increased in rats treated with dacomitinib (p 5 0.0018) indicating intestinal barrier dysfunction. Data presented as mean with SD. Data analysed using one-way ANOVA.
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the site of Na-K-dependent ATPase that drives the sodium pump. Further studies are required to examine the impact of dacomitinib on specific tight junction proteins. Although barrier dysfunction is emerging as a key driver of chemotherapy induced diarrhoea, this is the first study to implicate barrier dysfunction in the development of TKI induced diarrhoea, and will form the basis of further investigation.
Conclusions
In summary, this study has shown that dacomitinib induces severe ileal damage and gastrointestinal permeability in this model. The high expression of ErbB1 in the ileum was also accompanied by the localised damage seen only in this region. This is the first study to provide a detailed interrogation of the intestinal changes associated with dacomitinib treatment and advances our understanding of diarrhoea processes induced by not only this agent, but assists in further characterising the poorly understood mechanisms of ErbB TKI-induced diarrhoea.
